Angiochem

Develops Peptide drug conjugates for the treatment of neurological diseases

placeMontreal, Montreal, Canada calendar_todayFounded 2003 groups11 employees language angiochem.com

Registered entities

Innovation

44 patent families (18 granted) — focus: Human necessities, Chemistry & metallurgy; filing pace slowing. Cited 7,361 times.

YearFilings
201217
201314
201421
201521
201617
201713
20189
201910
20204
20212
20251

Investor mix

5 investors on record; lead investors include BDC, VIMAC Ventures.

Investor typeCountShare
Venture capital240%
Bank & private debt120%
Other / undisclosed240%
Coming soon